AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17132474
Drug: Transdermal oxybutynin
RxNorm normalized name: oxybutynin Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oxybutynin for 6 months or less
Trial: 9394816
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (fluticasone propionate)
Trial: 2446064
Drug: Ketanserin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 10 mg i.v. or 40 mg t.i.d. orally
Trial: 2446064
Drug: Ketanserin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 10 mg i.v.
Trial: 29961686
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) administered intravenously every 4 weeks (8 or 10 mg/kg based on weight) for 16 weeks, followed by random assignment to TCZ or placebo for 24 weeks.
Trial: 25424567
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS (1 mA) for 20 minutes daily over two weeks
Trial: 20051588
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg of 20% mannitol over 15 minutes
Trial: 20051588
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg of 20% mannitol over 15 minutes
Trial: 8908230
Drug: Intravenous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adrenaline (0.3 microgram/kg)
Trial: 1914761
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily in the morning (N = 104)
Trial: 1914761
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once daily at night (N = 106)
Trial: 30947606
Drug: Landmark-based corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landmark-based corticosteroid injection
Trial: 24664349
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g agave inulin
Trial: 24664349
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g agave inulin
Trial: 24664349
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g agave inulin)
Trial: 23011957
Drug: Various dose
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dose levels of the intervention
Trial: 12557801
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin plus intravaginal misoprostol (n = 36)
Trial: 12557801
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin plus placebo intravaginal (n = 34)
Trial: 12557801
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol plus intravenous placebo (n = 37)
Trial: 9602955
Drug: Intravenous famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous famotidine pretreatment
Trial: 27599225
Drug: Traditional in-office
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional in-office behavioral activation treatment for depression (BATD)
Trial: 22094954
Drug: Valganciclovir prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir prophylaxis (2 × 450 mg oral valganciclovir/day for 100 days)
Trial: 22094954
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (monitored by CMV-PCR, 2 × 900 mg valganciclovir/day for at least 14 days after positive PCR)
Trial: 18156412
Drug: 3 mg/d
RxNorm normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/d zinc in a liquid supplement
Trial: 18156412
Drug: 3 mg/d
RxNorm normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/d zinc in a fortified porridge
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during exercise
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during recovery from exercise
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced acidosis
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced alkalosis
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during acidosis
Trial: 7705376
Drug: Oral [13C]bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during alkalosis
Trial: 3314521
Drug: Meclofenamate sodium,
RxNorm normalized name: Meclofenamate Sodium, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium, 100 mg by mouth, three times a day
Trial: 28735173
Drug: Detached mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Detached mindfulness (DM; group treatment, twice weekly)
Trial: 28735173
Drug: Leisure activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leisure activities (control condition, twice weekly)
Trial: 26346941
Drug: NBI-98854 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-98854 (25 mg to 75 mg, once daily)
Trial: 24093950
Drug: Accelerated initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Accelerated initiation of renal replacement therapy (within 12 hours of eligibility)
Trial: 24093950
Drug: Standard initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation of renal replacement therapy (monitored over 7 days)
Trial: 19636689
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/d orally
Trial: 3042939
Drug: Pancrease (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrease (8 capsules daily)
Trial: 3042939
Drug: Eurobiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurobiol (2 bottles daily)
Trial: 31450908
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer screening adoption stages (pre-contemplation, contemplation, preparation, action, maintenance)
Trial: 25171898
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt plus probiotic capsules
Trial: 25171898
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt plus placebo capsules
Trial: 25171898
Drug: Control milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control milk plus probiotic capsules
Trial: 25171898
Drug: Control milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control milk plus placebo capsules
Trial: 21150558
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitors (any of the regimens including LPV/r)
Trial: 21150558
Drug: Nonboosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonboosted protease inhibitors
Trial: 21150558
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of protease inhibitor regimens
Trial: 18429758
Drug: Metformin (n=29)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (n=29)
Trial: 18429758
Drug: Continual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continual treatment with Metformin for 12 months (n=30)
Trial: 18429758
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (Control group, n=12)
Trial: 18429758
Drug: Patients never
RxNorm normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients never treated with Metformin (n=8)
Trial: 14640237
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 to 8 mg once-daily) added to ramipril (5 - 7.5 mg/day) for 16 weeks
Trial: 14640237
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to ramipril (5 - 7.5 mg/day) for 16 weeks
Trial: 8620276
Drug: Preoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative infusion cholangiography (PIC)
Trial: 6369522
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g/day) + Intensive antacid treatment
Trial: 6369522
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g/day) + Placebo treatment
Trial: 29775203
Drug: Optimal dynamic
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal dynamic treatment regime
Trial: 29775203
Drug: Sequential, multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential, multiple assignment randomized clinical trial
Trial: 12181246
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m²) followed by AC (60/600 mg/m²)
Trial: 12181246
Drug: AC (60/600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (60/600 mg/m²) followed by Docetaxel (100 mg/m²)
Trial: 10359886
Drug: AA-2414 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-2414 (80 mg/day)
Trial: 7732331
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg at bedtime)
Trial: 1695449
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, Aspirin) challenge
Trial: 108734
Drug: Intravenous THC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous THC, 30‐‐44.8 microgram/kg
Trial: 108734
Drug: Combined autonomic
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined autonomic blockade (i.v. saline, 0.04 mg/kg atropine sulfate, 0.2 mg/kg propranolol, or both)
Trial: 31786980
Drug: Serum urate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum urate level ≥6.8 mg/dL (hyperuricemia)
Trial: 31786980
Drug: Serum urate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum urate level 6.0 to <6.8 mg/dL
Trial: 31786980
Drug: Apparent treatment-resistant
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apparent treatment-resistant hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg on 3 antihypertensive medications or use of ≥4 antihypertensive medications)
Trial: 31786980
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of antihypertensive medication classes
Trial: 31786980
Drug: Serum urate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum urate level <6.0 mg/dL (reference)
Trial: 20473950
Drug: Solar vitamin
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solar vitamin D effective UV radiation (VD dose)
Trial: 19049753
Drug: ET‐AR antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐AR antagonist (sitaxsentan) 1 mg/kg
Trial: 19049753
Drug: ET‐AR antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐AR antagonist (sitaxsentan) higher doses
Trial: 19049753
Drug: ET‐AR antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐AR antagonist (sitaxsentan)
Trial: 26703220
Drug: Metformin 500mg
RxNorm normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg twice daily
Trial: 26703220
Drug: Ethinyl estradiol-cyproterone
RxNorm normalized name: cyproterone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl estradiol-cyproterone acetate for 21 days followed by 7 days drug-free
Trial: 24673793
Drug: Walnuts (28.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnuts (28.4 g, 6/week)
Trial: 15802405
Drug: Unopposed transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed transdermal estradiol (14 microg per day)
Trial: 12161495
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg daily with fatty liver (group C)
Trial: 12161495
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg daily without fatty liver (group B)
Trial: 10210764
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 1 mg twice a day on day 1, followed by metoclopramide 60 mg on day 2 and 3
Trial: 10210764
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 8 mg on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3
Trial: 10210764
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron followed by metoclopramide
Trial: 10210764
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus oral ondansetron
Trial: 1945205
Drug: Topical dihydrotestosterone
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical dihydrotestosterone
Trial: 31778823
Drug: GB001 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB001 20 mg
Trial: 27041692
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide plus G-CSF (Arm A)
Trial: 27041692
Drug: G-CSF alone
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF alone (Arm B)
Trial: 16330684
Drug: Candesartan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan at a target dose of 32 mg once daily
Trial: 10458211
Drug: Carboplatin at
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin at 100 mg/m2/wk concurrent with radiation therapy
Trial: 7597774
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (0.5 ml, 10 micrograms HBsAg)
Trial: 7597774
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (0.5 ml, 25 micrograms HBsAg)
Trial: 7597774
Drug: Yeast-derived recombinant
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived recombinant hepatitis B vaccine (0.5 ml, 10 micrograms HBsAg)
Trial: 7597774
Drug: Hevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac B (0.5 ml)
Trial: 6805026
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg CERM 3726
Trial: 6805026
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg CERM 3726
Trial: 6805026
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CERM 3726
Trial: 30427054
Drug: Midlateral subacromial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midlateral subacromial injection
Trial: 30427054
Drug: Posterior subacromial
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior subacromial injection
Trial: 27943533
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for anorexia nervosa (AN)
Trial: 22738209
Drug: 200-ml sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-ml sports drink with 1 g of GABA (trial G)
Trial: 22738209
Drug: 200-ml sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-ml sports drink without GABA (trial C)
Trial: 20035589
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) treatment for 6 months
Trial: 9722799
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS) 200 microgram once daily
Trial: 9722799
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS) plus loratadine
Trial: 9722799
Drug: Placebo (aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (aqueous nasal spray plus tablet)
Trial: 9722799
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS)
Trial: 2527121
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (oral, 1 g once daily)
Trial: 2527121
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (intravenous, 500 mg in 100 ml of physiological saline)
Trial: 415478
Drug: Cyclophosphamide, vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, vincristine, prednisone, and doxorubicine or VM 26 (induction chemotherapy course for 15-20 days)
Trial: 415478
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with cyclophosphamide, vincristine, and prednisone only
Trial: 31163332
Drug: MI‐CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI‐CBT plus treatment as usual (TAU)
Trial: 28433465
Drug: Carbohydrate-rich beverage
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich beverage (440 kcal/300 mL)
Trial: 28433465
Drug: Fat-rich beverage
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich beverage (440 kcal/300 mL)
Trial: 17722521
Drug: Silicon gel
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon gel sheet alone
Trial: 17722521
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of onion extract and silicon gel sheet
Trial: 10091203
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg once daily for 1 year)
Trial: 7529520
Drug: Aprotinin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1 x 10(6) kallikrein inactivator units (KIU) as an intravenous bolus and 1 x 10(6) KIU added to the pump prime)
Trial: 29488152
Drug: DS-8500a 25
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 25 mg
Trial: 29071087
Drug: DS-8500a 75
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 75 mg
Trial: 26310621
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) 15 mg/kg body weight
Trial: 26310621
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% sodium chloride solution)
Trial: 23538970
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER (75‐300 mg/day)
Trial: 23538970
Drug: fluoxetine (20‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine (20‐60 mg/day)
Trial: 21282194
Drug: Clade 1
RxNorm normalized name: INFLUENZA A VIRUS A/VIETNAM/1203/2004 (H5N1, CLADE 1) ANTIGEN (FORMALDEHYDE INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clade 1 HA vaccine followed by clade 2 HA vaccine
Trial: 21282194
Drug: Schedule of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule of injections at days 0 and 14
Trial: 21282194
Drug: Schedule of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule of injections at days 0 and 28